drugset / Trial / NCT03278808

Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis

NCT03278808

RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open label, Phase 2 study with controlled human malaria infection (CHMI). Twenty three subjects will be enrolled into 2 groups (15 subjects in the Chloroquine-Azithromycin \[CQ/AZ\] Intervention Group, and 8 subjects in the Chloroquine \[CQ\] Group). The CQ/AZ Group will receive experimental intervention of 300 mg of CQ and 2 g of azithromycin (AZ). The CQ Group will receive 300 mg of CQ only. All subjects will participate in the CHMI and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.

Timeline

Start
2018-09-17
Primary completion
2019-12-30
Completion
2020-01-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 2 g Oral
Comparator Chloroquine Small molecule 300 mg Oral
Background CYCLOGUANIL Small molecule

Indications